Charlton Hill, Co-founder and Head of Innovation at Uncanny Valley, a Sydney-based progressive music technology company discusses the company’s ambitions to speed-up, democratize and re-shape music production through the use of artificial intelligence.

In late summer 2021, athletes with disabilities from around the world competed at the Tokyo 2020 Paralympic Games. Maja Hoock, Manager of Corporate Communications Research and Development (R&D) at the leading German prosthetics company, Ottobock, explains how IP-protected sports prostheses help athletes make the most of their abilities.

Having spent the last 20 years scribbling notes and drawing tournament brackets to calculate how long they would take I’ve finally got round to...

A look at the 5 best melatonin gummies in the US of 2021. We have slept on each one and broken them down into beginner to advanced.

We look at the best CBD for athletes. Learn how to use CBD for focus, recovery and healing for sports. The top 3 products are...

This tutorial will take you step-by-step to build a temperature converter website. For the full project spec, you can check it out on DevProjects!

Dutch GP organisers have had to inform a third of the ticketed spectators for the forthcoming Formula 1 race at Zandvoort that they can no longer attend. With government authorities ruling that only two thirds of the sell-out 105,000-capacity audience may attend due to covid, race organisers devised a sort […]

The post Bad news for 70,000 Dutch GP ticket holders appeared first on Cyber Flows.

In 18 June 2021, a Full bench of the Federal Court of Australia (Middleton, Nicholas, and Burley JJ) unanimously upheld a decision of a single judge of the court (Beach J), finding that a method of detecting cell-free foetal DNA (cffDNA) in maternal blood serum comprises patent-eligible subject matter (i.e. a ‘manner of manufacture’) under Australian law: Ariosa Diagnostics, Inc v Sequenom, Inc [2021] FCAFC 101.  The patent at issue is Australian patent no. 727,919, covering an invention originally developed by Oxford University researchers, and subsequently transferred to Sequenom Inc.  The patent expired in March 2018, however a live dispute remains because Ariosa Diagnostics licensed its ‘Harmony Test’ – which Sequenom says (and the Full Court has agreed) infringes the patent – for use in Australia since at least September 2015.

To my mind, the result in this case is neither particularly surprising nor contentious.  The patent claims are directed to a method of detecting cffDNA.  While the method is underpinned by the naturally occurring fact – not known until its discovery by the inventors prior to March 1997 – that cffDNA is present in maternal blood serum, a useful method of detecting a previously unknown natural phenomenon, having a practical application, has long been considered patentable.  Ariosa’s arguments that Sequenom’s claims were in substance directed to the ‘mere’ discovery itself, resulted only in the production of ‘information’, and therefore unpatentable, were unsuccessful.  And while the broad scope of the main claim in this case might raise other issues, such as obviousness or sufficiency of description, these matters have also been addressed at first instance and/or on appeal, and are separate from the question of subject matter eligibility. 

Nonetheless, this case will generate some interest, if only because the result in Australia is opposed to the outcome of equivalent litigation between Sequenom and Ariosa involving a corresponding patent in the United States.  In that case, a narrower claim than in Australia was found to be directed to an unpatentable natural phenomenon.  The result was controversial, not least because a number of judges on the US Court of Appeals for the Federal Circuit (CAFC) – including Judge Linn on the original panel (Ariosa Diagnostics, Inc.v. Sequenom, Inc. (Fed. Cir. 2015)) and Judges Lourie and Dyk in a decision refusing en banc rehearing – indicated that they felt bound by the Supreme Court precedents, but did not agree with the outcome.  There was therefore great disappointment when the US Supreme Court declined to hear an appeal.

The outcome of the Australian appeal is not all bad news for Ariosa, however, with the finding of the primary judge on infringement being partially reversed.  In particular, there were periods during which the Harmony Test was not carried out in Australia, but instead samples were sent to the US for testing by Ariosa, which the primary judge found also to be infringing actions.  The Full Court has disagreed, finding that ‘importing’ the information resulting from the tests into Australia did not comprise a relevant ‘exploitation’ of the claimed method, as it might have done were the product of the method a physical article.

Read more »

As with any other industry, it is important to keep staff motivated in supply chain and logistics. Motivating your employees helps create a climate of continuous improvement. Employee engagement should not be underestimated as it can have an impact on the general costs of the company. This is because it is directly linked to the […]

The post How to motivate supply chain/logistics staff? appeared first on Globalior.

This month some documents were leaked regarding what was previously known as Rainbow Six Quarantine. The game was meant to be a spin-off from...

A new “double perovskite” material could become a more environmentally friendly platform for spintronics devices...